Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Wall painting following terminal cleaning with a chlorine solution as part of an intervention to control an outbreak of carbapenem-resistant Acinetobacter baumannii in a neurosurgical intensive care unit in Israel.
Dickstein Y, Eluk O, Warman S, Aboalheja W, Alon T, Firan I, Putler RKB, Hussein K. Dickstein Y, et al. J Infect Chemother. 2021 Oct;27(10):1423-1428. doi: 10.1016/j.jiac.2021.05.017. Epub 2021 May 31. J Infect Chemother. 2021. PMID: 34083145
Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group. Dickstein Y, et al. Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988. Clin Infect Dis. 2019. PMID: 30462182 Clinical Trial.
Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial.
Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, Neuberger A, Ghanem-Zoubi N, Santoro A, Eliakim-Raz N, Pertzov B, Steinmetz T, Stern A, Dickstein Y, Maroun E, Zayyad H, Bishara J, Alon D, Edel Y, Goldberg E, Venturelli C, Mussini C, Leibovici L, Paul M; Bacteremia Duration Study Group. Yahav D, et al. Among authors: dickstein y. Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. doi: 10.1093/cid/ciy1054. Clin Infect Dis. 2019. PMID: 30535100 Clinical Trial.
Antimicrobial use trends, Israel, 2012 to 2017.
Dickstein Y, Temkin E, Ben-David D, Carmeli Y, Schwaber MJ. Dickstein Y, et al. Euro Surveill. 2019 Aug;24(34):1900022. doi: 10.2807/1560-7917.ES.2019.24.34.1900022. Euro Surveill. 2019. PMID: 31456558 Free PMC article.
Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rognås V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA Study Group. Dickstein Y, et al. Clin Infect Dis. 2020 Dec 17;71(10):2599-2607. doi: 10.1093/cid/ciz1146. Clin Infect Dis. 2020. PMID: 31758195 Clinical Trial.
Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A, Lellouche J, Temkin E, Daikos G, Skiada A, Durante-Mangoni E, Dishon-Benattar Y, Bitterman R, Yahav D, Daitch V, Bernardo M, Iossa D, Zusman O, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Clin Microbiol Infect. 2020 Sep;26(9):1185-1191. doi: 10.1016/j.cmi.2020.03.035. Epub 2020 Apr 3. Clin Microbiol Infect. 2020. PMID: 32251844 Free article. Clinical Trial.
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity.
Daitch V, Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Cavezza G, Adler A, Dickstein Y, Pavleas I, Zampino R, Bitterman R, Zayyad H, Koppel F, Zak-Doron Y, Levi I, Babich T, Turjeman A, Ben-Zvi H, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L. Daitch V, et al. Among authors: dickstein y. BMC Infect Dis. 2021 Mar 31;21(1):309. doi: 10.1186/s12879-021-05995-y. BMC Infect Dis. 2021. PMID: 33789574 Free PMC article.
A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens.
Henderson A, Bursle E, Stewart A, Harris PNA, Paterson D, Chatfield MD, Paul M, Dickstein Y, Rodriguez-Baño J, Turnidge JD, Kahlmeter G. Henderson A, et al. Among authors: dickstein y. Clin Microbiol Infect. 2021 Dec;27(12):1746-1753. doi: 10.1016/j.cmi.2021.03.019. Epub 2021 Apr 1. Clin Microbiol Infect. 2021. PMID: 33813125 Free article. Review.
In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections.
Nutman A, Temkin E, Lellouche J, Rakovitsky N, Hameir A, Daikos G, Durante-Mangoni E, Pavleas I, Dishon Y, Petersiel N, Yahav D, Eliakim N, Bernardo M, Iossa D, Friberg LE, Theuretzbacher U, Leibovici L, Paul M, Carmeli Y; AIDA Study Group. Nutman A, et al. Clin Microbiol Infect. 2022 Jan;28(1):73-78. doi: 10.1016/j.cmi.2021.05.005. Epub 2021 May 11. Clin Microbiol Infect. 2022. PMID: 33984488 Free article.
49 results